SecBot SecBot
SC 13D/A ·Filed Nov 6, 2026

VIR

Vir Biotechnology, Inc.
BEARISH
Impact 5/10
Horizondays Processed10d 5h ago SEC0001012975-26-001020
Activist stake amendment (position change)
Actionable Insight ▼ Bearish

ARCH's reduction from 7.4% to 6.9% and explicit disavowal of activist plans signals a passive posture. Monitor whether further selling continues below the 5% threshold, which would eliminate the 13D filing requirement and reduce overhang.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$13.65
T+0 close · Nov 6, 2026 · via day close
Latest settled
−29.79%
T+5 · $9.58
Vs SPY
−28.10%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $13.65entry
  2. T+1 · 7d ago −3.63%α −3.26% · $13.15
  3. T+5 · 18h ago −29.79%α −28.10% · $9.58
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ARCH Venture Fund IX and affiliates sold 796,175 shares of Vir Biotechnology over November 3-5, 2026, reducing their aggregate beneficial ownership from 7.4% to 6.9% (based on 171.3M shares outstanding). The filing states no current plans for board changes, extraordinary transactions, or other control-related actions, marking a de-escalation from prior activist positioning.

Key Financial Metrics

Stake
6.9%
Investor
ARCH Venture Fund IX, L.P.

Key Facts

  • ARCH Venture Fund IX and ARCH Venture Fund IX Overage sold a combined 796,175 shares of Vir Biotechnology common stock from November 3-5, 2026.
  • Weighted average sale prices ranged from $11.24 to $12.06 per share across four trading days.
  • Aggregate beneficial ownership of the ARCH reporting persons decreased to 6.9% from 7.4% in the prior filing.
  • The filing explicitly states no present plans for board changes, mergers, asset sales, or other extraordinary transactions.
  • The sale occurred just two days after Vir's Q3 2026 earnings release (November 4, 2026) which reported a narrower net loss of $96.3M.

Financial Impact

ARCH sold 796,175 shares at approximately $11.24-$12.06 per share, representing about 0.5% of shares outstanding.

dilutionownership

Risk Factors

  • Continued selling by ARCH could further pressure the stock.
  • ARCH's exit below 5% would remove a major supportive shareholder and reduce public scrutiny.
  • No activist catalysts remain; stock direction depends solely on pipeline data (Phase 3 ECLIPSE 1 results expected Q4 2026).

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13D/A Filing (Primary)0001012975-26-001020
Document: 0001012975-26-001020-index.html0001012975-26-001020
Document: 0001012975-26-001020.txt0001012975-26-001020

Track record

36 reports on VIR

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +26.32% at T+20 after the Oct 14, 2026 report. 4 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry $9.84 Now $9.58 +2.64% settles Nov 23
  2. Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
  3. Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
  4. Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
  5. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
  6. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
  7. Nov 6, 202610d ago SC 13D/A Bearish 5/10 Viewing Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
  8. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
  10. Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 9h

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026